key: cord-0882508-s6dsw2t2 authors: Krishnamurthy, Arvind; Gopinath, Kodaganur S. title: The Need for Prioritizing Cancer Surgeries Amidst the COVID-19 Pandemic date: 2020-04-29 journal: Indian J Surg Oncol DOI: 10.1007/s13193-020-01080-z sha: 6bb3be2d70f749303f8b2e4002a7cb91c63d339f doc_id: 882508 cord_uid: s6dsw2t2 nan The COVID-19 pandemic has posed and continues to pose unprecedented challenges for patients, oncologists as well as the health care systems across the world [1] . The Surgical Oncology community seems to have more questions than answers, especially when it comes to issues concerning prioritization of cancer care, amidst this unrelenting pandemic. Patients with cancer are more vulnerable to infections in general because of their underlying disease as well as their immunosuppressed status; consequently they represent a high-risk group in the COVID-19 pandemic [2] . Surgical oncologists are unsure of the ultimate benefit of their interventions i.e. cancer surgeries, especially when it has to be weighed against the risk of introducing an inadvertent COVID-19 infection in the health care system. There are a few guidelines developed by cancer centres/ surgical oncology societies to aid the treating oncologist in making complex treatment decisions [3, 4] . However, considering that the COVID-19 pandemic is a new respiratory infection, the available evidences are limited and hence most of the guidelines give only very broad rather than any specific recommendations. The treating oncologists must keep reminding themselves that these guidelines must be interpreted only after taking into consideration ones clinical judgement, institutional protocols, the available resources and more importantly the prevalence of COVID-19 infections in their region. The severity of the COVID-19 pandemic may vary over time and hence all the available guidelines are subject to periodic changes with the changing trajectory of pandemic and with the accumulation of newer evidences. A multidisciplinary discussion for dealing with such complex cancer scenarios is hence strongly encouraged. The COVID-19 pandemic has once again brought to the forefront the myriad issues concerning the safety of the cancer patients as well as the treating health care workers. The potential risks, especially for the cancer patients seems to emanate from the limited evidences that suggest that the signs and symptoms of COVID-19 tend to be more severe in cancer patients than in patients without cancer. Further, radical treatments for cancer can predispose the patients to more serious and at times fatal outcomes of the COVID-19 infection. These findings were based on a small, but much criticized study by Liang et al. [4] of 18 cancer patients out of a cohort of 1590 patients, interestingly 13 (72%) of eighteen cancer patients had a prior radical surgical resection. The authors concluded that there was an increased risk of intensive care admissions and mortality among the cancer patients with COVID-19 as compared to the COVID-19 patients without cancer [4] . Further, there are clear evidences to suggest that older patients and also patients with increased comorbidities tend to have poorer outcomes with COVID 19 infection [5] ; these issues assume greater significance while managing an elderly cancer patient with comorbidities. The lower case fatality rate of COVID-19 logically seems to suggest that the benefits of treating selected cancer patients (who are otherwise fit and healthy) may far outweigh the risks of dying from COVID-19 [6] . It is vitally important for the treating oncologists to clearly explain the above evidences to cancer patients during the process of informed consenting. Further, the risk of inhospital transmission of COVID-19 infection can be mitigated by effective implementation of the infection control policies, especially with regard to screening and triaging patients and staff for symptoms of Severe Acute Respiratory Illness (SARI) as well as the disciplined use and disposal of the Personal protective equipment (PPE) and the other biomedical waste. Treating surgical oncologists as well as treating oncology institutions must ideally develop their own multidisciplinary protocols for prioritizing cancer treatments after taking into account all the ground realities amidst the pandemic [6, 7] . All patients scheduled for cancer surgeries should be managed with all the due precautions (Universal and Respiratory) in dedicated health care settings and by trained and well informed (by ensuring periodic training of the protocols) health care workers. Certain broad surgical considerations, commonly seen across among the various guidelines include [6, 7] Finally the treating oncologists must be aware and must fully abide by the protocols as laid down by the Government, knowing fully well that in case of a conflict, the Governmental protocols supersede all the other guidelines. The decision for starting or delaying a cancer surgery should ideally be made by a shared decision making process and should be individualized for each patient. The oncology community will have to wait with bated breaths the true impact of the COVID-19 pandemic on the long term outcomes of cancer patients i.e. especially the survival outcomes of cancer patients whose surgeries and/or other therapies were either compromised, delayed or cancelled, this would be an important area for deeper introspection and future research. COVID-19: global consequences for oncology COVID-19 and cancer: lessons from a pooled meta-analysis Apr) Society of Surgical Oncology. Management of Cancer Surgery Cases during the COVID-19 pandemic: considerations Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan ) Cancer, COVID-19 and the precautionary principle: prioritizing treatment during a global pandemic A war on two fronts: cancer Care in the Time of COVID-19 11) Virtually perfect? Telemedicine for Covid-19 Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations